Ivana Gotthardová, Martin Javorský, Ivan Tkáč
Incretin effect enhancers are drugs used in the treatment of Type 2 diabetes during last decade and include GLP-1 receptor
agonists and dipeptidyl peptidase-4 inhibitors (gliptins). There is a considerable inter-individual variability in glycaemic
response to treatment with incretin mimetics and as etiological factor genetic background of the individual may
be involved. Variants in several genes were shown to be involved in the physiology of incretin secretion. Only variants
of CTRB1/2, TCF7L2, GLP1R a CDKAL1 genes have also evidence from pharmacogenetic studies. After the replication in
further studies, these observations could be of clinical significance in helping to identify patients with potentially lower
or higher response to gliptin treatment.